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Tissue regeneration and wound healing are severely impaired in diabetes and are
associated with poor circulation and dysfunctional blood vessels. Angiotensin II inhibitors
are anti-hypertensive drugs used in clinical practice to regulate blood pressure and could
affect tissue remodeling. We hypothesize that blocking angiotensin II, using Losartan,
could facilitate tissue regeneration in diabetic mice. To this end, we established an
experimental model of wound healing in streptozotocin-induced diabetic mice. Our data
demonstrated that Losartan accelerates wound repair and normalizes wound stromal
responses, having a beneficial role in wounds of diabetic individuals. Our findings highlight
a potential therapeutic use of Losartan in improving wound repair in diabetic conditions.
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Introduction
Tissue regeneration is required for restoring organ function after injury or during the renewal
of tissues. The most common example of tissue regeneration in the adult organism is wound
healing. Wound healing is a dynamic process requiring soluble mediators, blood and parenchymal
cells, as well as extensive extracellular matrix remodeling (Eming et al., 2014). Wound repair
can be divided into at least three overlapping processes: an initial phase that involves a vascular
response leading to hemostasis and an inflammatory reaction protecting the organism from
pathogen invasion, a second phase that contributes to tissue regeneration and a third phase that
comprises a tissue remodeling process (Werner and Grose, 2003). Initially, the damage of the
blood vessels during a deep injury triggers platelet coagulation and the development of fibrin clot
that temporary seals the wound. Both platelets and infiltrating inflammatory cells release growth
factors, cytokines, and proteinases that contribute to the formation of new tissue. The second
phase is characterized by extensive cellular activity, which involves proliferation of keratinocytes
at the wound edge and migration into the wound where they form a multilayer undifferentiated
epidermis. Hyperproliferative and migrating keratinocytes express specific keratins of the basal
epidermal layer, which denote a poor level of differentiation, such as keratin 14 and keratin 5
(Alam et al., 2011). Concomitantly, fibroblasts migrate into the wound and differentiate into
myofibroblasts contributing to wound contraction and to the deposition of additional matrix,
mainly in the form of collagen. The new tissue generated at the injured dermis- called granulation
tissue- is rich in inflammatory cells, myofibroblasts and newly formed capillaries. The development
of new vasculature at the wound edge is necessary to sustain the newly formed tissue and to support
keratinocyte migration, though the secretion of growth factors and extracellular matrix remodeling
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(Gurtner et al., 2008). At the last phase of would healing,
a reduction in cellularity and extensive extracellular matrix
remodeling, contribute to differentiation and resolution of
keratinocyte layers and the regression of the granulation tissue
in the dermis, thus restoring tissue structural integrity and
physiologic functionality.
Impaired wound healing responses and chronic ulcers are
the hallmarks of diabetes, a metabolic disease that affects
many individuals worldwide. According to the WHO the global
prevalence of diabetes in adults is 9% for the 2014 and more than
1.5 million deaths are directly attributed to diabetes. Wounds of
diabetic mice exhibit prolonged inflammation, microvasculature
aberrations that result in irregular circulation and diminished
angiogenesis and decreased collagen production (Eming et al.,
2007; Seitz et al., 2010). The expression of various growth factors,
such as the keratinocyte growth factor, is either reduced, delayed,
or absent in the wound tissue of diabetic mice, especially during
re-epithelisation and granulation tissue formation (Werner et al.,
1994). Similarly, the production of pro-angiogenic growth
factors, such as the vascular endothelial growth factor (VEGF)
and members of the family of fibroblast growth factors (FGF),
which facilitates the wound healing process is greatly decreased
or absent (Frank et al., 1995; Xu and Zou, 2009). Consistent
with an important role for the microvasculature in repairing
wounds of diabetic mice, the topical application of VEGF or ex
vivo cultured endothelial progenitor cells seems to accelerate the
wound repair in diabetic mice (Galiano et al., 2004; Asai et al.,
2013).
Evidence suggests that components of the Renin-Angiotensin
system, known as the RAS plays an important role in the
pathogenesis of wound repair and tissue reconstruction in
diabetes (Cooper, 2004). Specifically, angiotensin II, the active
biological component of this system, acts through two receptor
subtypes AT1 ans AT2 to control systemic blood pressure and
blockers of Angiotensin II action are systematically used in
clinical practice as anti-hypertensive drugs. Clinical evidence
suggests that the use of AT1 inhibitors in diabetic patients reduces
the risk of cardiovascular and renal complications (Cooper,
2004; Rask-Madsen and King, 2013). Apart from its function
in controlling blood pressure, Angiotensin II regulates cell
proliferation, migration, and collagen metabolism (Ren et al.,
2013); all processes important for wound healing. Therefore,
we hypothesize that inhibition of Angiotensin II could facilitate
tissue regeneration in diabetes. To this end, we established a
wound healing protocol in streptozotocin-induced diabetic mice
and examined the effect of a clinically widely used, competitive
AT1 inhibitor, Losartan, Gavras and Salerno (1996) in regulating
tissue regeneration.
Materials and Methods
Experimental Mouse Model of Streptozotocin
(STZ)-induced Diabetes
Male mice C57BL/6J, 8–10 weeks of age, were fasted prior to
STZ (Fisher Scientific) administration for 4 h. A solution of
22.5mg/ml STZ in sodium citrate buffer was prepared fresh
before each injection. Mice were weighted and the appropriate
volume of STZ-citrate solution was injected intraperitoneal (i.p.)
in each mouse, so that the final dose was 150mg STZ/Kg
mouse. STZ-treated mice were supplied with 10% sucrose in
water overnight to protect against sudden hypoglycemia. Glucose
levels were measured 2 days after STZ administration and then
monitored closely for 2 and 4 weeks, using AlphaTrak glucose
meter and strips, specially calibrated for mice (Abbot). Mice
became diabetic (blood glucose levels above 400mg/dl) 2–4 days
post STZ injection. Diabetic mice received daily subcutaneaous
injections of insulin. At 4-weeks post STZ administration,
diabetic and control mice were treated with the angiotensin II
inhibitor Lozartan for the 14 days duration of the wound healing
experiment. Losartan was obtained as pills from the pharmacy,
crushed, dissolved in PBS and administered by oral gavage, to
control and diabetic mice, daily, at a concentration of 10mg/Kg.
In VivoWound Healing
Skin wounds of 2mm diameter (2 wounds per mouse) were
generated, using a sterile biopsy punch, in the shaved dorsal
back of the different experimental cohorts of 6–8 mice, per
condition, 2 and 4 weeks post-induction of diabetes. The in vivo
wound healing experiment was repeated 3 times. Wounded skin
was collected at different time points of the healing process for
analysis.
Hematoxylin-eosin Staining and
Masson-trichrome Staining and Morphological
Analysis
Excised wounds were bisected along the arterior-posterior axis
of the skin, fixed in 4% PFA, de-hydrated and then embedded
in paraffin. Sections of 4µm thickness from the middle of the
wound were stained with hematoxylin and eosin, to examine
wound morphology. At day 3, the wound width was quantified as
the distance of the gap between the two migrating multilayered
epithelial fronts across the wound and expressed as % open
wound= [wound width (mm) ∗100/ initial wound size of 2mm].
The collagen fibers were visualized using Masson-trichrome
staining. At day 7, the granulation area of the wound was
measured as the distance of the gap between the blue stained
collagen fibers of the two sides of the wounded dermis (mm).
Keratinocyte thickness was estimated by measuring the depth of
the epithelial multilayer in the middle of the wound. All images
were captured from a Nikon Eclipse TE 300 light microscope.
Areas of granulation tissue, keratinocyte thickness and open
wound were measured using Image J (National Institutes of
Health, Bethesda, Md.). All quantifications were performed by
two different investigators, in a double-blinded fashion.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissue sections were de-
paraffinized in xylene, rehydrated through graded alcohols
and stained for endothelial cells, α-smooth muscle actin (α-
SMA)- positive cells and undifferentiated keratinocytes. Antigen
retrieval was performed using Proteinase K solution (10mg/ml)
at 37◦C for 15min. The sections were then blocked in 2% goat
serum and 1% BSA solution in PBS and incubated with primary
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antibodies against endomucine (1:100, Sigma), α-SMA (1:200,
Sigma) and Keratin-14 (1:50, Covance), overnight, at 4◦C. After
washing with PBS, tissue sections were subsequently incubated
with anti-rat Alexa Fluor 546 antibody (1:500, Molecular Probes)
for 60min at room temperature and mounted in mounting
reagent. DAPI was used to stain cell nuclei. Fluorescence
images were acquired using the AxioObserved Z1 Microscope
(Carl Zeiss, Germany). Quantification of immunofluorescence
was performed in a blinded fashion by measuring the pixel
area of the fluorescent intensity for endomucin and α-SMA
staining, respectively, by Image J (National Institutes of Health,
Bethesda, MD).
Ethical Regulations
All animals were housed at BSRC Al. Fleming animal facilities
and all experiments were performed in accordance with the
European Legal Framework for the Protection of animals used
for scientific purposes (European Directive 86/609/EEC).
Statistical Analyses
The non-parametric Mann-Whitney U rank sum test was
performed for the quantitative analysis of wound repair.
Values are expressed as mean ± SEM. P-values less than
0.05 were considered statistically significant. Statistical analysis
was performed with GraphPad Prism, Version 4.0 (GraphPad
Software Inc., La Jolla, CA, USA).
Results
Establishing the Tissue Regeneration Diabetic
Mouse Model
To study the potential interplay between hypertension and tissue
regeneration in diabetic conditions, we combined the extensively
used streptozotocin-induced diabetic model (Wu and Huan,
2008) with the in vivo tissue regeneration model of skin wound
healing (Gurtner et al., 2008; Wood and Eming, 2012; Eming
et al., 2014). Streptozotocin (STZ) is a nitrosurea compound
derived from Streptomycin achromogenes that is toxic for the
pancreatic β cells and causes pancreatic dysfunction associated
with local immune responses, leading to hypoinsulinemia
and hyperglycemia in animals (Rees and Alcolado, 2005).
Administration of high doses of STZ (150mg/Kg) generated
diabetic mice with high blood glucose levels (Table 1). Diabetic
mice were treated with insulin to avoid adverse effects of
hypoinsulinemia and hyperglycemia, including dehydration,
severe weight loss, extensive nephropathy, and neuropathy.
Under the experimental conditions used, the weight of diabetic
mice was similar to control (Table 1), indicating the lack
of diabetic complications 4 weeks after STZ injection. To
establish the tissue regeneration model, male C57BL/6J mice
were split into experimental cohorts (6–8 mice): 4-weeks
Diabetic mice, 4 weeks Diabetic mice treated with Losartan
(Diabetic and Los), non-diabetic (ND) mice, and non-diabetic
mice treated with Losartan (ND and Los). We didn’t observe
any difference between ND and ND treated with Losartan
(Supplementary Figure 1) and therefore we merge the data of
these groups to generate the control group. The anti-hypertensive
TABLE 1 | Glucose measurements and weight in different experimental
groups.
Glucose measurements
ND ND and
Los
Diabetic Diabetic and
Los
Before STZ
(mg/dl)
145 ± 15
(n = 12)
157 ± 40
(n = 14)
138 ± 15
(n = 13)
169 ± 26
(n = 16)
2 weeks after
STZ (mg/dl)
176 ± 33
(n = 12)
176 ± 20
(n = 14)
588 ± 73
(n = 13)
580 ± 112
(n = 16)
4 weeks after
STZ (mg/dl)
187 ± 25
(n = 9)
202 ± 46
(n = 12)
563 ± 119
(n = 9)
558 ± 128
(n = 13)
Weight (g) 21.8 ± 1.4
(n = 13)
22 ± 2
(n = 14)
20.8 ± 2.2
(n = 9)
22.7 ± 2
(n = 14)
ND, non-diabetic; STZ, streptozotocin; Los, Angiotensin II inhibitor (Losartan).
Values are mean ± s.e.m.
drug, Losartan- an inhibitor of Angiotensin II function- was
administrated during the wound healing process. Daily oral
administration of Losartan did not alter the blood glucose levels,
nor had any effect on the weight of control and diabetic mice
(Table 1). We performed skin wounds in the dorsal back of all
cohorts, and we assessed the ability of skin to regenerate under
the different conditions of the experimental groups.
Angiotensin II Inhibitors Accelerate Wound
Healing in Diabetic Mice
First we examined the healing process of 3-days wounds.
Wounded skin sections from control, diabetic, and diabetic
treated with losartan mice were subjected to qualitative and
quantitative analysis. We performed hematoxylin and eosin
(HE) staining to examine the tissue morphology and Masson-
trichrome staining to visualize collagen fibers in the surrounding
unwounded dermis. In all experimental groups, the wound
healing process had been initiated and keratinocytes of the
epidermis had started their migration to close the wound
(Figure 1). We quantified the open wound width of 3-day
wounds by measuring the distance between the gap between the
leading epithelial edges and express it as % of the initial wounded
area. As expected, we found that diabetic mice had significantly
more open wounds compared to controls. In contrast, daily
administration of the hypertensive drug, losartan, accelerated
the process of wound healing and decreased the opening of the
wound similarly to control group (Figure 1).
Inhibition of Angiotensin II Enhance Tissue
Remodeling of 7-days Wounds in Diabetic Mice
Next we performed qualitative and quantitative analysis of
skin sections derived from 7-days wounds. Hematoxylin and
eosin staining revealed the multi-layered epidermis formed by
proliferative and migrating keratinocytes and the underlying
granulation tissue (Figure 2). At this stage of wound healing,
granulation tissue starts to resolve and the extracellular matrix
of the dermis gets remodeled and produce large collagen fibers
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FIGURE 1 | Analysis of wounded skin following 3 days of healing
process. Treatment with angiotensin II inhibitor decreased the extensive
wounded skin area observed in diabetic mice. (A–C) Haematoxylin and eosin
staining of formalin fixed and paraffin embedded skin tissue sections from
control (A), diabetic (B), and diabetic treated with losartan (C) mice. (D–F)
Masson-trichrome staining of skin tissue sections from control (D), diabetic
(E), and diabetic treated with losartan (F) mice. (G) Quantification of (%)
wound width, which remained open after 3 days of healing. Values are mean ±
s.e.m., *p < 0.05, Mann-Whitney test. Arrows indicate edges of migrating
epithelial fronts in open wounds. Scale bar 100µm. Los: Losartan.
that can be depicted by Masson-trichrome staining (Figure 2).
We observed that the diabetic mice displayed a delay in the
collagen fiber formation that was reversed by administration of
Losartan. We quantified the width of the wound granulation area
by measuring the distance between the collagen fibers of the two
sides of the wounded dermis, marking the wounded area and
found that the granulation area in diabetic mice was significantly
larger than the control mice, indicating impaired resolution
and extracellular matrix remodeling. In contrast, the wound
granulation area of diabetic mice treated with the Angiotensin
II inhibitor, Losartan, was similar to control group (Figure 2).
Another indication of wound resolution is the thickness of
the initially formed epidermis. Initially, keratinocytes that have
proliferated and migrated to close the wound form a multi-
layer undifferentiated epidermis. Subsequently, keratinocytes
cease proliferation and differentiate, decreasing the thickness
and altering the morphology of the initially formed epidermis.
The diabetic mice displayed increased thickness of the newly
assembled epidermis compared to control group (Figure 2).
Consistent with Losartan stimulating the wound healing
response, the depth of epidermal layers in diabetic mice treated
with the angiotensin II inhibitor, was similar to control group and
thinner than diabetic mice (Figure 2). Taken these data together,
FIGURE 2 | Analysis of wounded skin following 7 days of healing
process. (A–C) Haematoxylin and eosin staining of formalin fixed and paraffin
embedded skin tissue sections from control (A), diabetic (B), and diabetic
treated with losartan (C) mice. (D–F) Masson-trichrome staining of skin tissue
sections from control (D), diabetic (E), and diabetic treated with losartan (F)
mice. Quantification of granulation tissue width (mm) (G) and the depth of
newly formed keratinocyte layers (mm) (H) in control, diabetic and diabetic
treated with Losartan mice. Both the area of the granulation tissue and the
thickness of the newly formed epidermis in diabetic mice treated with losartan
are similar to control and decreased compared with non-treated diabetic mice,
indicating an accelerated wound healing response. Arrows indicate edges of
granulation tissue area. Values are mean ± s.e.m., *p < 0.05, **p < 0.01,
Mann-Whitney test. Arrows indicate edges of collagen fibers at the two sides
of the wounded dermis. Scale bar 100µm. Los: Losartan.
Losartan facilitated the remodeling of 7-days wounds in diabetic
mice and displayed a comparable to control wound morphology.
No Adverse Effect of Angiotensin II Inhibitors in
Healed Wounds
Lastly, we examined skin sections of fully closed and resolved
wounds. As expected, after 14 days of wound healing, the skin
epidermis was fully differentiated and new hair follicles were
developed in all experimental groups (Figure 3). The granulation
tissue was fully resolved and a collagen-rich matrix assembled
in skin dermis of all experimental mice (Figure 3). We did not
observe any morphological differences in the skin of diabetic
mice treated with Angiotensin II inhibitor compared to control
group, indicating that Losartan does not affect normal skin.
Angiotensin II Inhibitors Normalise Wound
Stroma
To gain insight into the mechanism of Losartan function in
accelerating wound healing in diabetic mice, we investigated
further the wound healing process. Intrigued by the reduced
wound opening and the decreased granulation area observed in
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FIGURE 3 | Analysis of wounded skin following 14 days of healing
process. No differences were observed among the different experimental
groups at 14 days post-wounded. Closed wounds exhibited collagen staining
and formation of new hair follicles. (A–C) Haematoxylin and eosin staining of
formalin fixed and paraffin embedded skin tissue sections from control (A),
diabetic (B), and diabetic treated with losartan (C) mice. (D–F)
Masson-trichrome staining of skin tissue sections from control (D), diabetic (E)
and diabetic treated with losartan (F) mice. Scale bar 100µm. Los: Losartan.
wounds of diabetic mice treated with Losartan, we hypothesize
that inhibiting Angiotensin II could alter the contraction capacity
of the wound. Thus, we examined the presence of myofibroblasts,
the cell constituent of wound stroma that is responsible for tissue
contraction (Li and Wang, 2011), by staining wound sections
with α-smooth muscle actin (α-SMA). The wounds of diabetic
mice seem to have lower levels of α-SMA expression, compared
to the other groups (Figure 4). Treatment with Losartan reverted
this phenotype. The presence of α-SMA positive cells in wounds
of diabetic mice treated with Losartan was similar to control
group (Figure 4).
Expression of α-SMA is also present in pericytes and smooth
muscle cells surrounding blood vessels. Altered permeability
of existing vasculature and the formation of new blood vessel
are required for tissue regeneration and might explain the
differences in the wound healing of diabetic mice elicited by
Losartan treatment. The analysis of wound sections stained
with α-SMA revealed increased number of larger structures
that resemble blood vessels. Therefore, we sought to analyse
differences in the presence of blood vessels in wound stroma.
We examined wounds of mice that were still open or recently
bridged together as indicated by a thin layer of undifferentiated
keratinocytes, stained by keratin-14 (Figure 5), as these wounds
have active angiogenesis (Eming et al., 2007). Staining of wound
sections with endomucin, a marker of vascular endothelial
cells revealed that wound stroma of diabetic mice treated with
Losartan was rich in blood vessel, similar to control group
(Figure 5). Consistent with the impaired vascular function that
is associated with diabetes, wound stroma from diabetic mice
had fewer blood vessels compared to control or diabetic treated
with Lozartan group (Figure 5). Taken together, these findings
indicate that Losartan could affect wound contraction and blood
vessel function, acting to normalize the wound stroma and
facilitate wound healing in diabetic mice.
FIGURE 4 | Immunofluorescence analysis of α-SMA expression on
wounded murine skin tissue sections. Formalin fixed paraffin embedded
tissue was stained for α-SMA (red). Cell nuclei were stained with DAPI (blue).
Examples are shown from control (A), diabetic (B), and diabetic treated with
losartan (C) mice. The granulation tissue area in diabetic mice treated with
Losartan (C,I) display similar to control (A,G) and increased compared with
diabetic non-treated mice (B,H), number of a-SMA positive cells. (D–I)
Magnification of the areas marked in (A–C) with the white boxes. (J)
Quantification of a-SMA immunofluorescence (pixel area, arbitrary units). White
arrowheads indicate blood vessels and yellow arrowheads indicate
myofibroblasts. Values are mean ± s.e.m., ***p < 0.001, Mann-Whitney test.
Discussion
Tissue regeneration is severely impaired in diabetes, as
exemplified by chronic wounds and ulcers and microvasculature
aberrations. In diabetic skin tissues the renin angiotensin system
is activated with increased expression of angiotensin II and
elevated expression ratio between the type 1 (AT1) and type
2 (AT2) receptors (Hao et al., 2011). The purpose of the
current study was to elucidate whether the treatment with the
angiotensin II inhibitor, Losartan (an anti-hypertensive drug)
affects tissue regeneration in diabetes. For this we examined the
wound healing process of the skin epidermis in streptozotocin-
induced diabetic mice. We found that treatment with Losartan
for the duration of the wound healing process accelerated tissue
regeneration and reversed the morphological alterations induced
by diabetes.
We didn’t observe any difference in wound healing responses
between non-diabetic and non-diabetic mice treated with
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FIGURE 5 | Immunofluorescence analysis of newly formed epidermis
and skin blood vessels. Formalin fixed paraffin embedded tissue sections
were stained for undifferentiated epidermal cells by keratin-14 (green) and
vascular endothelium by endomucin (red) from control (A), diabetic (B), and
diabetic treated with losartan (C) mice. Cell nuclei were stained with DAPI
(blue). The granulation tissue of diabetic mice treated with losartan (C,F)
seems to show a higher degree of vascularization when compared to diabetic
mice (B,E) or control (A,D). (D–F) Magnification of the areas marked in (A–C)
with the white boxes. (G) Quantification of endomucin immunofluorescence
(pixel area, arbitrary units). Values are mean ± s.e.m., ***p < 0.001,
Mann-Whitney test.
Losartan. However, complete depletion of the AT1 receptor
delayed the wound healing in the skin of mice (Kawaguchi
et al., 2004; Yahata et al., 2006). One possible explanation of
this discrepancy could be that, in contrast to an acute inhibition
of the AT1 receptor through the administration of a selective
drug, chronic absence of AT1 action might have generated
compensatory signals from AT2 receptor or the angiotensin-
converting enzyme (ACE), which could differentially influence
wound healing responses. It is well established that the final
outcome of Angiotensin II function is tightly controlled by the
action of AT1 and AT2 receptors, which often exhibit opposing
effects and the angiotensin-converting enzyme (ACE) (Tamarat
et al., 2002; Takeda et al., 2004; Yahata et al., 2006). Based on
our data showing that angiotensin II inhibition facilitates the
wound healing under diabetic conditions, it would be interested
to examine the effect of AT1 deletion in diabetes.
Several studies have elucidated the main defects of wound
healing in diabetes (Werner et al., 1994; Loots et al., 1998). This
disease is mainly characterized by severe vascular abnormalities
as a result of blood vessel dysfunction that can directly influence
the wound healing process, both on the initial anti-inflammatory
stage and on the re-epithelisation phase and reconstitution of the
injured dermis, leading to important delays on the onset of the
reaction and dysfunction in keratinocyte migration, extracellular
matrix remodeling, and resolution of the granulation tissue.
Consistent with this, all phases of the wound healing process
were impaired in streptozotocin-induced diabetic animals. The
re-epithelisation was significantly delayed at 3-days of wound
healing and both the area of granulation tissue and the thickness
of the newly formed undifferentiated epidermis were increased
at 7-days wounds. Treatment with Losartan for the duration
of the wound healing process was sufficient to reverse these
morphological differences and to induce a normal-like wound
healing response in diabetic mice. The decreased granulation
area and the restoration of collagen production in the wounds of
diabetic mice treated with Losartan indicate reduced fibrosis and
sufficient remodeling of extracellular matrix. Our data agree with
studies showing that Losartan can decrease profibrotic signals by
inhibiting thrombospondin -1 and transforming growth factor
(TGF)-β1 action and downregulating connective tissue growth
factor (CCN2) (Chauhan et al., 2013). Additionally, treatment
of primary fibroblasts isolated from diabetic skin with Losartan
downregulated the TGF-β1 and TIMP-1 expression that seem to
be involved in the impaired collagen formation of the diabetic
skin (Ren et al., 2013).
Our findings suggest that inhibition of angiotensin II function
in diabetes could normalize skin responses and facilitate tissue
regeneration. We observed that Losartan treatment of diabetic
mice resulted in an enrichment of sma-expressing myofibroblasts
and a higher degree of vascularization in the wound stroma,
facilitating wound contraction and normalizing wound healing
responses. The decreased number of sma-positive cells detected
in the wounds of diabetic mice could contribute to the impaired
wound healing. It is well established that myofibroblasts have
essential roles in wound healing, secreting growth factors that
facilitate the proliferation and migration of epithelial cells, and
mediating the mechanical contraction of the wound (Werner
and Grose, 2003; Li and Wang, 2011; Eming et al., 2014).
Consistent with this, a recent study showed that the presence
of a-SMA positive peripheral blood cells and myofibroblasts
accelerates the wound repair process in a diabetic mouse model,
mainly by promoting cell proliferation, re-epithelialization, and
angiogenesis (Kao et al., 2011). Conflicting data exists regarding
the effect of AT1 inhibitors in angiogenesis. It has been
reported that angiotensin II signaling through AT1 receptor
increase vascular endothelial growth factor (VEGF) expression
and facilitates vascular permeability and angiogenesis (Fujita,
2004; Suganuma et al., 2005). In contrast to the above studies,
Losartan treatment was shown to improve vascular perfusion
and decompress blood vessels in tumors, without affecting VEGF
expression (Diop-Frimpong et al., 2011; Chauhan et al., 2013).
Our data are consistent with a vascular normalization effect
of angiotensin II inhibitor, which promotes wound healing in
diabetes. There is evidence that a normalized and a healthy
peripheral circulation in diabetic mice improve cutaneous wound
healing (Pietramaggiori et al., 2009). Also, a recent study showed
that pretreatment of streptozotocin-induced diabetic mice with
a mixture of pro-angiogenic growth factors and endothelial
progenitor cells (EPCs) accelerated incisional wound healing
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(Ackermann et al., 2014), indicating that restoring a functional
vasculature in diabetes could improve the wound repair process
and facilitate tissue regeneration.
Taken together, our results revealed a beneficial role
of losartan in accelerating cutaneous wound healing in a
streptozotocin-induced diabetic mouse model, by restoring
wound stroma responses through its action on blood vessels and
myofibroblasts. Further studies will elucidate the precise role of
this antihypertensive drug in facilitating tissue regeneration of
different organs in diabetic conditions. Given that Losartan is a
safe drug, already used in clinical practice to treat hypertension,
our results highlight a novel therapeutic approach that could have
a possibly direct clinical impact on improving cutaneous wound
therapy for diabetic patients.
Supplementary Material
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphys.
2015.00170/abstract
Supplementary Figure 1 | Losartan has no effect on the wound healing of
non diabetic mice. (A) Quantification of (%) wound width, which remained open
after 3 days of healing, as in Figure 1. (B) Quantification of granulation tissue
width (mm) in 7-days wounds, as in Figure 2. Values are mean ± s.e.m.
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